Howard M Katzenstein
Overview
Explore the profile of Howard M Katzenstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, et al.
Clin Genitourin Cancer
. 2024 Nov;
22(6):102238.
PMID: 39532048
Introduction: In JAVELIN Bladder 100, avelumab first-line maintenance (1LM) improved overall survival (OS) and progression-free survival (PFS) in patients with locally advanced/metastatic urothelial carcinoma (la/mUC) without progression following 1L platinum-based...
2.
Voeller J, Katzenstein H, Naranjo A, Tenney S, Chen L, London W, et al.
Pediatr Blood Cancer
. 2024 Nov;
72(1):e31407.
PMID: 39502014
Background: Tumor invasion of the spinal canal is detected radiographically in approximately 15% of patients with newly diagnosed neuroblastoma (NB). The optimal clinical approach to maintain excellent survival outcomes while...
3.
ONeill A, Trobaugh-Lotrario A, Geller J, Hiyama E, Watanabe K, Aerts I, et al.
EClinicalMedicine
. 2024 Feb;
69:102446.
PMID: 38384339
Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50-70% of the time while children with advanced hepatocellular carcinoma...
4.
Gupta S, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Su C, et al.
Oncologist
. 2023 Oct;
29(3):244-253.
PMID: 37846191
Background: The treatment landscape for locally advanced/metastatic urothelial carcinoma (la/mUC) has evolved. This study examined US prescribing patterns and clinical decision-making for first-line (1L) and first-line maintenance (1LM) treatment. Materials...
5.
ONeill A, Meyers R, Katzenstein H, Geller J, Tiao G, Lopez-Terrada D, et al.
Pediatr Blood Cancer
. 2023 Jul;
70 Suppl 6:e30576.
PMID: 37495540
Liver tumors account for approximately 1%-2% of all pediatric malignancies, with the two most common tumors being hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Previous Children's Oncology Group studies have meaningfully...
6.
Thompson P, Malogolowkin M, Furman W, Piao J, Krailo M, Chung N, et al.
Pediatr Blood Cancer
. 2023 Apr;
70(7):e30365.
PMID: 37073741
Background: Survival for children with metastatic hepatoblastoma (HB) remains suboptimal. We report the response rate and outcome of two courses of vincristine/irinotecan/temsirolimus (VIT) in children with high-risk (HR)/metastatic HB. Procedures:...
7.
Vasudevan S, Meyers R, Finegold M, Lopez-Terrada D, Ranganathan S, Dunn S, et al.
J Pediatr Surg
. 2022 Jul;
57(10):251-256.
PMID: 35810020
Background: Hepatoblastoma (HB) requires surgical resection for cure, but only 20-30% of patients have resectable disease at diagnosis. Patients who undergo partial hepatectomy at diagnosis have historically received 4-6 cycles...
8.
Trobaugh-Lotrario A, Katzenstein H, Ranganathan S, Lopez-Terrada D, Krailo M, Piao J, et al.
J Clin Oncol
. 2021 Dec;
40(5):459-467.
PMID: 34874751
Purpose: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Children's Oncology Group (COG) study AHEP0731 underwent...
9.
Katzenstein H, Malogolowkin M, Krailo M, Piao J, Towbin A, McCarville M, et al.
Cancer
. 2021 Nov;
128(5):1057-1065.
PMID: 34762296
Background: The Children's Oncology Group (COG) adopted cisplatin, 5-flourouracil, and vincristine (C5V) as standard therapy after the INT-0098 legacy study showed statistically equivalent survival but less toxicity in comparison with...
10.
Seligson N, Maradiaga R, Stets C, Katzenstein H, Millis S, Rogers A, et al.
NPJ Precis Oncol
. 2021 May;
5(1):43.
PMID: 34021224
Sarcomas harboring EWSR1-NFATc2 fusions have historically been categorized and treated as Ewing sarcoma. Emerging evidence suggests unique molecular characteristics and chemotherapy sensitivities in EWSR1-NFATc2 fusion positive sarcomas. Comprehensive genomic profiles...